Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia

M. Imran Aslam; Anthony P. Cardile; George E. Crawford

doi:10.1177/2325957413502539

Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia

M. Imran Aslam, Anthony P. Cardile, George E. Crawford

Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.

Original language	English (US)
Pages (from-to)	22-23
Number of pages	2
Journal	Journal of the International Association of Providers of AIDS Care
Volume	13
Issue number	1
DOIs	https://doi.org/10.1177/2325957413502539
State	Published - Jan 1 2014

Keywords

HIV
peptide thrombopoietin receptor agonist
primary HIV-associated thrombocytopenia
romiplostim
thrombocytopenia

ASJC Scopus subject areas

Immunology
Dermatology
Infectious Diseases

Access to Document

10.1177/2325957413502539

Fingerprint Dive into the research topics of 'Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia'. Together they form a unique fingerprint.

Cite this

@article{a4d5dfc958b54e5cbf96c77ac9f6f0a9,

title = "Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia",

abstract = "Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.",

keywords = "HIV, peptide thrombopoietin receptor agonist, primary HIV-associated thrombocytopenia, romiplostim, thrombocytopenia",

author = "Aslam, {M. Imran} and Cardile, {Anthony P.} and Crawford, {George E.}",

year = "2014",

month = jan,

day = "1",

doi = "10.1177/2325957413502539",

language = "English (US)",

volume = "13",

pages = "22--23",

journal = "Journal of the International Association of Providers of AIDS Care",

issn = "2325-9574",

publisher = "SAGE Publications Inc.",

number = "1",

}

TY - JOUR

T1 - Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia

AU - Aslam, M. Imran

AU - Cardile, Anthony P.

AU - Crawford, George E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.

AB - Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.

KW - HIV

KW - peptide thrombopoietin receptor agonist

KW - primary HIV-associated thrombocytopenia

KW - romiplostim

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84893081217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893081217&partnerID=8YFLogxK

U2 - 10.1177/2325957413502539

DO - 10.1177/2325957413502539

M3 - Article

C2 - 24036490

AN - SCOPUS:84893081217

VL - 13

SP - 22

EP - 23

JO - Journal of the International Association of Providers of AIDS Care

JF - Journal of the International Association of Providers of AIDS Care

SN - 2325-9574

IS - 1

ER -

Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this